Wilkinson GR - Search Results

1

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.

Takahashi H, Wilkinson GR, Padrini R, Echizen H. Takahashi H, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 2004 May;75(5):376-80. doi: 10.1016/j.clpt.2004.01.007. Clin Pharmacol Ther. 2004. PMID: 15116049 Review. No abstract available.

2

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H. Takahashi H, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 2003 Mar;73(3):253-63. doi: 10.1067/mcp.2003.26a. Clin Pharmacol Ther. 2003. PMID: 12621390

3

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.

Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H. Takahashi H, et al. Among authors: wilkinson gr. Blood. 2004 Apr 15;103(8):3055-7. doi: 10.1182/blood-2003-07-2521. Epub 2003 Dec 30. Blood. 2004. PMID: 15070684 Free article.

4

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Takahashi H, et al. Among authors: wilkinson gr. Pharmacogenet Genomics. 2006 Feb;16(2):101-10. doi: 10.1097/01.fpc.0000184955.08453.a8. Pharmacogenet Genomics. 2006. PMID: 16424822

5

Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren.

Takahashi H, Kim RB, Perry PR, Wilkinson GR. Takahashi H, et al. Among authors: wilkinson gr. J Pharmacol Exp Ther. 1997 Apr;281(1):297-303. J Pharmacol Exp Ther. 1997. PMID: 9103510

6

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.

Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR. Tateishi T, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 2001 May;69(5):333-9. doi: 10.1067/mcp.2001.115447. Clin Pharmacol Ther. 2001. PMID: 11372001 Clinical Trial.

7

Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.

Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Adedoyin A, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1998 Jul;64(1):8-17. doi: 10.1016/S0009-9236(98)90017-0. Clin Pharmacol Ther. 1998. PMID: 9695714 Clinical Trial.

8

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.

Masica AL, Mayo G, Wilkinson GR. Masica AL, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 2004 Oct;76(4):341-9. doi: 10.1016/j.clpt.2004.07.003. Clin Pharmacol Ther. 2004. PMID: 15470333 Clinical Trial.

9

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.

Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. Wandel C, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 2000 Jul;68(1):82-91. doi: 10.1067/mcp.2000.108506. Clin Pharmacol Ther. 2000. PMID: 10945319

10

Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.

Wilkinson GR. Wilkinson GR. Clin Pharmacol Ther. 2004 Aug;76(2):99-103. doi: 10.1016/j.clpt.2004.04.005. Clin Pharmacol Ther. 2004. PMID: 15289786 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page